Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
9 Downloads (Pure)


A recently published paper addressed the interesting topic of prevention of erectile dysfunction (ED) with tadalafil, a phosphodiesterase-type 5 inhibitor (PDE5i) in patients undergoing radiation therapy for localized prostate cancer.(1) Tadalafil 5 mg or placebo was administered once-daily for 24 weeks in patients undergoing external-beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer. This randomized trial did not show superior efficacy of the active drug compared with placebo 4-6 weeks after stopping the study drug. Furthermore, patients younger than 65 years did not respond significantly better than older patients.
Original languageUndefined/Unknown
Pages (from-to)664-665
Number of pages2
JournalAsian Journal of Andrology
Issue number5
Publication statusPublished - 2014

Research programs

  • EMC MM-03-32-04

Cite this